The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

PubWeight™: 1.46‹?› | Rank: Top 5%

🔗 View Article (PMC 3369725)

Published in ACS Chem Neurosci on October 21, 2010

Authors

Pavitra Kannan1, Sanjay Telu, Suneet Shukla, Suresh V Ambudkar, Victor W Pike, Christer Halldin, Michael M Gottesman, Robert B Innis, Matthew D Hall

Author Affiliations

1: Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland, 20892, USA; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Articles citing this

Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A (2011) 1.03

P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. J Adv Res (2014) 1.00

Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Pharmacology (2012) 0.99

The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together. J Biol Chem (2012) 0.97

Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96

PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab (2011) 0.95

Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med (2013) 0.94

Genetic knockdown and pharmacological inhibition of parasite multidrug resistance transporters disrupts egg production in Schistosoma mansoni. PLoS Negl Trop Dis (2011) 0.92

A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab (2012) 0.91

Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles. J Control Release (2012) 0.91

Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One (2013) 0.88

Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar. J Nucl Med (2014) 0.87

Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1). PLoS One (2013) 0.87

Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem (2011) 0.85

A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. Eur J Nucl Med Mol Imaging (2011) 0.84

Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier. Mol Pharm (2013) 0.82

The Inhibitor Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther (2015) 0.82

Transport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos. Mol Reprod Dev (2014) 0.81

Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel. PLoS Negl Trop Dis (2014) 0.81

[11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein. EJNMMI Res (2012) 0.81

Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. Nucl Med Biol (2012) 0.81

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer Res (2015) 0.81

Cancer stem cell metabolism: a potential target for cancer therapy. Mol Cancer (2016) 0.80

Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors. Pharmaceutics (2011) 0.80

Marine natural products as breast cancer resistance protein inhibitors. Mar Drugs (2015) 0.80

Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier. Clin Pharmacol Ther (2016) 0.79

Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein. J Biol Chem (2015) 0.79

Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci (2012) 0.79

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. EJNMMI Res (2015) 0.79

In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochem Pharmacol (2011) 0.78

Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. Eur J Pharmacol (2012) 0.78

A high throughput flow cytometric assay platform targeting transporter inhibition. Drug Discov Today Technol (2014) 0.78

Multiple Drug Transport Pathways through Human P-Glycoprotein. Biochemistry (2015) 0.78

Synthesis and evaluation of new fluorine-18 labeled verapamil analogs to investigate the function of P-glycoprotein in the blood-brain barrier. ACS Chem Neurosci (2017) 0.76

CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis (2016) 0.76

Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. Drug Metab Dispos (2015) 0.75

In silico identified targeted inhibitors of P-glycoprotein overcome multidrug resistance in human cancer cells in culture. Pharmacol Res Perspect (2015) 0.75

Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration. Antimicrob Agents Chemother (2015) 0.75

Benzanilide-Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators. ACS Med Chem Lett (2013) 0.75

(99m)Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study. J Biol Inorg Chem (2013) 0.75

Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[(11) C]verapamil in elderly vs. young subjects. Br J Clin Pharmacol (2017) 0.75

Articles cited by this

Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72

Commentary. Lysosomotropic agents. Biochem Pharmacol (1974) 12.28

Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79

Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87

P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther (2007) 2.11

Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol (1998) 1.94

The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol (1999) 1.84

Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res (2004) 1.82

Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77

Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci (2006) 1.66

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62

The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry (2006) 1.45

The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2004) 1.42

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett (1999) 1.38

Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem (1997) 1.38

Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther (2006) 1.37

Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem (2009) 1.25

Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res (2000) 1.24

A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22

Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20

In vivo site-directed radiotracers: a mini-review. Nucl Med Biol (2008) 1.19

Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. Ann Nucl Med (2010) 1.16

Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13

Exploiting reaction intermediates of the ATPase reaction to elucidate the mechanism of transport by P-glycoprotein (ABCB1). J Biol Chem (2006) 1.01

N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98

Practical demethylation of aryl methyl ethers using an odorless thiol reagent. Arch Pharm Res (2008) 0.81

Articles by these authors

A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18

Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55

An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98

Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab (2003) 3.77

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72

P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66

Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76

Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab (2002) 2.58

Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52

Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage (2007) 2.50

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32

Sex-specific fitness effects of nutrient intake on reproduction and lifespan. Curr Biol (2008) 2.32

Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31

The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26

Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25

PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med (2006) 2.20

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15

Synthesis and evaluation in monkey of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem (2007) 2.11

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04

Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med (2010) 2.00

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97

Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage (2007) 1.91

Fast and high-yield microreactor syntheses of ortho-substituted [(18)F]fluoroarenes from reactions of [(18)F]fluoride ion with diaryliodonium salts. J Org Chem (2010) 1.91

Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91

Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med (2005) 1.89

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89

Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage (2009) 1.89

Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85

Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83

Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med (2007) 1.81

Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79

Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry (2003) 1.77

Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp (2004) 1.76

Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry (2002) 1.75

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62

Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61

A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab (2012) 1.59

Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging (2008) 1.58

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57

PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res (2010) 1.55

The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54

Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54

Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med (2008) 1.54

Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53

P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med (2008) 1.53

Approaches to quantify radioligands that wash out slowly from target organs. Eur J Nucl Med Mol Imaging (2010) 1.52

VAMP2-dependent exocytosis regulates plasma membrane insertion of TRPC3 channels and contributes to agonist-stimulated Ca2+ influx. Mol Cell (2004) 1.49

Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48

Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry (2009) 1.47

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46

Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46

The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry (2006) 1.45

Syntheses of 11C- and 18F-labeled carboxylic esters within a hydrodynamically-driven micro-reactor. Lab Chip (2004) 1.44

Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry (2006) 1.44

Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem (2008) 1.43

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain (2006) 1.43

Image-derived input function for brain PET studies: many challenges and few opportunities. J Cereb Blood Flow Metab (2011) 1.42

Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage (2009) 1.42

The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res (2005) 1.42

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41

Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry (2005) 1.40

Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell (2003) 1.40

Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38

Application of calibrated image-derived input function to a clinical protocol. Nucl Med Commun (2014) 1.38